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Abstract 
Background:  Men with prostate cancer are reported as commonly using 
Complementary and Alternative Medicine (CAM) but surveys have not recently been 
subjected to a rigorous systematic review incorporating quality assessment.   
Materials and Methods:  Six electronic databases were searched using pre-defined 
terms.  Detailed information was extracted systematically from each relevant article.  
Study reporting quality was assessed using a Quality Assessment Tool which 
demonstrated acceptable inter-rater reliability and produces a % score. 
Results:  42 studies are reviewed.  All were published in English between 1999 and 
2009; 60% were conducted in the USA.  The reporting quality was mixed (median score 
= 66%, range 23% - 94%).  Significant heterogeneity precluded formal meta-analysis.  
39 studies covering 11,736 men reported overall prevalence of CAM use; this ranged 
from 8% to 90% (median = 30%).  10 studies reported prevalence of CAM use 
specifically for cancer care; this ranged from 8% to 50% (median = 30%).  Some 
evidence suggested CAM use is more common in men with higher education/incomes 
and more severe disease.    
Conclusions: The prevalence of CAM use among men with prostate cancer varies 
greatly across studies.  Future studies should use standardised and validated data 
collection techniques to reduce bias and enhance comparability.   
 
Keywords:  alternative therapies, complementary therapies, prostatic neoplasms, 
review, surveys. 
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Introduction 
Prostate cancer is the most prevalent cancer among men in the Western hemisphere.  
Since the advent of Prostate Specific Antigen (PSA) testing, detection and hence 
incidence of prostate cancer have increased, and earlier (and improved) treatments 
have led to decreased mortality (1-3).  Initial treatment options for men with localised 
prostate cancer in the UK are: watchful waiting, active surveillance, radical 
prostatectomy, external beam radiotherapy, brachytherapy, high intensity focused 
ultrasound, cryotherapy(4).  However, there is a paucity of high quality evidence 
comparing these treatments to guide patients and clinicians in their treatment choices 
(5) and adverse effects including impotence are common, persistent and associated 
with reduced quality of life (6, 7).  Men with prostate cancer may choose to supplement 
their conventional treatment with one or more forms of complementary or alternative 
medicine (CAM).   
 The National Center for Complementary and Alternative Medicine (NCCAM) 
defines CAM as “a group of diverse medical and health care systems, practices, and 
products that are not generally considered part of conventional medicine”(8) and 
identifies five groups of such interventions: whole medical systems (e.g. Ayurveda), 
mind-body medicine (e.g. meditation), biologically based practices (e.g. dietary 
supplements), manipulative and body-based practices (e.g. chiropractic), and energy 
medicine (e.g. Reiki).  Of the biologically based practices, saw palmetto is particularly 
well known for prostate health and its popularity has generated both safety and 
efficacy research (9, 10).  The patented dietary supplement PC-SPES was promoted for 
and became particularly popular among men with prostate cancer; this induced trials 
that reported both beneficial and adverse effects (11-13). Safety concerns were then 
raised that led to the eventual withdrawal of PC-SPES in the USA due to contamination 
(see the National Cancer Institute for summary (14)).  Since the withdrawal of PC-SPES, 
large-scale studies have been carried out on other biologically based practices for 
prostate health, notably the SELECT trial of vitamin E and selenium for cancer 
prevention (15). 
Surveys on CAM use in prostate cancer have not recently been subjected to a 
rigorous systematic review incorporating quality assessment.  Previous reviews on the 
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subject need up-dating and do not provide detailed information focused on CAM use 
in prostate cancer (16-18).  Currently, this makes it difficult to have confidence in 
assertions about the prevalence of CAM use in prostate cancer.  Furthermore, a 
comprehensive up-to-date review would provide useful information for oncologists 
that could aide their communication with patients about CAM, inform the research 
community as to gaps and inconsistencies in this literature and possibly identify new 
research areas.  We therefore carried out a systematic review of surveys on CAM use by 
men with prostate cancer.  Our primary aims were to evaluate the prevalence of use of 
CAM overall and of specific CAM modalities.  Our secondary aims were: to assess the 
methodological quality of the surveys; to explore the consistency of findings regarding 
factors associated with CAM use (clinical and demographic characteristics and study 
characteristics such as date, geographical location, quality); and to explore common 
reasons for CAM use.   
Methods 
Literature	Search	
Our search strategy was designed to identify primary research studies investigating the 
prevalence of CAM use (i.e. surveys).  Studies examining the outcomes of specific 
therapies (e.g. clinical trials, cohort studies) were excluded, as were qualitative studies. 
We included full publications published in journals and excluded the ‘gray’ literature 
(e.g. conference proceedings or letters).  Six electronic databases were searched for 
articles meeting the above criteria: Medline (1950 – 06/09), AMED (1985 – 06/09), 
CINAHL (1982 – 06/09), EMBASE (1980 – 06/09), PsychINFO (1985 – 06/09), Web of 
Science (1970 – 06/09).  We have described our pre-specified search strategies 
elsewhere (19).  In brief, we used the following MeSH terms plus free-text equivalents 
as required for each database:  “complementary therapies [exploded]” AND “neoplasms 
[exploded]” AND “data collection [exploded]”.  We used End Note Web 2.2 to organise 
the identified references.  Titles and abstracts were reviewed for eligibility.  If these 
contained insufficient information, the complete article was obtained.  We did not 
restrict our searches by language, but did not identify any eligible non-English 
language papers.   
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Data	Extraction	and	Quality	Assessment	
Detailed information related to data collection and results was extracted systematically 
from each paper and entered into a pre-designed Excel spreadsheet.   
We used a quality assessment tool (QAT) for surveys initially developed in the 
context of a systematic review of CAM use in pediatric cancer (19), which 
demonstrated good inter-rater reliability.  This tool was based on the specific checklist 
for cross-sectional studies of the Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) Statement (20). For the present review we removed two 
unnecessary items concerning patient gender and cancer diagnosis. In the resulting 
15-item QAT the original weighting of items was retained giving a maximum total 
score of 15.5 points.  A percentage score was used as an indicator of overall reporting 
quality, as not all criteria apply to each paper.  Scoring the papers (rather than merely 
describing their strengths and limitations) allowed us to explore more easily the 
relationship between reporting quality and outcomes.  All papers were scored by two 
investigators, and according to Cohen’s Kappa the inter-rater reliability of all but one 
item was substantial (kappa above 0.6 (21)) or almost perfect (kappa above 0.8 (21); 
Table 1); the overall scale had excellent inter-rater reliability (kappa = 0.88).   
A number of papers in our review reported on the prevalence of CAM use in 
prostate cancer and in other types of cancer or the general population.  For these 
papers, data extraction focused exclusively on data specific to the subgroup of 
patients with prostate cancer.  However, quality assessment was carried out 
considering the entire paper.   
Statistical	Analyses	
We used standard descriptive statistics and Forest plots to depict prevalence rates of 
overall CAM use and of specific CAM modalities.  If studies reported multiple 
prevalence rates, the rate for CAM use since cancer diagnosis was selected.  The 
relationships between prevalence rates and study-level factors (time, geographical 
location, quality) were explored graphically.  The relationships between CAM use and 
patient-level factors (socio-demographic and clinical characteristics) were explored by 
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examining findings across studies. Too few studies reported sufficient information 
consistently to allow more formal statistical analyses.  Furthermore, due to the 
heterogeneity of the included data we were unable to pool prevalence data in a meta-
analysis. 
Results 
Study	Selection	and	Characteristics	
We identified 2311 unique references (after removing 753 duplicates), of which 297 
reported on the prevalence of CAM use by patients with any type of cancer.  We 
excluded 255 studies as they reported CAM use either in other specific cancer 
populations (e.g. breast cancer, colorectal cancer) or in un-differentiated cancer 
populations (i.e. a study may have surveyed men with prostate cancer but not reported 
the prevalence of CAM use in this group alone).  Forty-two studies reported on the 
prevalence of CAM use among men with prostate cancer, and are included in this 
review (22-63).  However, only seventeen of these studies focused exclusively on men 
with prostate cancer (22, 24, 28, 29, 34, 36, 37, 39, 40, 50, 51, 54, 56, 58-60, 62).  
The remaining studies collected data from broader study populations and reported the 
prevalence of CAM use for subgroups including men with prostate cancer (23, 25-27, 
30-33, 35, 38, 41-49, 52, 53, 55, 57, 61, 63).  The characteristics of all 42 included 
studies are summarised in Table 2.  They were all published in English between 1999 
and 2009.  Most (25, 60%) were conducted in the USA.   
Twenty one studies reported some information about time since diagnosis with 
prostate cancer (22, 24, 25, 27, 29-31, 33, 35, 39, 43, 45, 48-50, 53, 54, 56, 59, 60, 
63) using a range of formats (e.g. minimum, maximum, range, mean).  Some studies 
surveyed men who were recently diagnosed (e.g. Steginga et al.’s participants were, on 
average, 4.25 weeks post-diagnosis at the baseline survey point (56)) while others 
included men who had been diagnosed many years previously (e.g. 16% of Wilkinson et 
al.’s participants had been diagnosed at least 5 years before the survey (59)).  Thirteen 
studies reported some information about the stage of cancer at diagnosis, including 
clinical stage, Gleason score, presence of metastases, and/or PSA levels (22, 28, 34, 
36, 40, 45, 50, 51, 53, 58-60, 62).  The variety of indicators used, and statistics 
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reported (e.g. percentages, means), precludes any meaningful summary of this data, 
but Table 2 describes the disease characteristics of participants as reported in each 
study.  Sixteen studies reported the conventional medical treatments used by their 
participants for prostate cancer (22, 23, 25, 28, 29, 34, 35, 37, 40, 50, 54, 56, 58-60, 
62).  These findings are summarised in Table 3.  Sixteen studies reported the 
participants’ age (22, 28, 29, 34, 35, 37, 40, 50, 51, 53, 54, 56, 58-60, 62). Mean age 
ranged from 61.5 years (56) to 70 years (59) in 15 studies. Thirteen studies reported 
some information about the educational level of their participants (22, 28, 29, 35, 39, 
51, 53, 54, 56, 58-60, 62).  High school was completed by 73% (60) to 96% (51) of 
participants in 12 studies 
Reporting	Quality	
Reporting quality was mixed, and total QAT scores ranged from 23% to 94% (median = 
66%) (Table 1)   In summary, the included literature was adequate for assessing and 
reporting prevalence of specific CAM modalities; clearly defining CAM both in the 
paper and for the survey respondents; reporting participants’ characteristics, in 
particular age and SES indicators; reporting response rates.  The weaknesses we 
identified were:  common use of data collection strategies that are subject to recall 
bias (i.e. that ask participants to recall their CAM use over a period of more than 12 
months or that do not specify a recall period); lack of reporting of pilot-testing of 
measures of CAM use; collecting data from samples that are unlikely to be 
representative of the general population of men with prostate cancer. 
Prevalence	of	CAM	use	
Prevalence rates for overall use of CAM (as defined by individual studies) were reported 
in 39 studies including data on 11,736 men with prostate cancer (22-29, 31, 33, 34, 
36-63).  Across these studies, the prevalence of CAM use ranged from 8% to 90%, 
while the inter-quartile range was 25% to 43% (median = 30%).  Sollner et al (55) report 
the lowest prevalence rate (8%) but this is based on a very small sample size (n=12).  
Three of the four studies reporting prevalence rates above 60% focused on the use of 
dietary or nutritional supplements (45, 54, 60), which are a broad class of therapies 
some of which (e.g. multivitamins) might now be considered conventional self-care 
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rather than CAM.  The other study reporting over 60% CAM use focused on the use of 
self-prayer for health (52) - the status of this practice as a form of CAM has also been 
questioned (64). 
As shown in Figure 1, 24 of the 39 studies reported how many men used CAM 
since their cancer diagnosis (22, 24, 27-29, 31, 34, 39, 40, 42-45, 48, 51, 53-61), 
and 10 of these reported how many men used CAM specifically for their cancer care 
(22, 29, 31, 34, 39, 40, 42, 51, 55, 56).  When considering the 24 studies reporting 
CAM use since diagnosis, prevalence of CAM use still ranged from 8% (55) to 90% (54) 
(median = 31%).  However, when selecting only the 10 studies reporting CAM use for 
cancer care, the reported prevalence rates ranged from 8% (55) to 50% (51) (median = 
30%).  This suggests that CAM use specifically for cancer care appears to be less 
variable than CAM use in general, amongst men with prostate cancer.   
Prevalence rates for use of specific CAM modalities were also reported by a 
number of studies.  Here we focus on the 5 CAM modalities reported most frequently 
across studies (see Figure 2).  Eleven studies reported prevalence of saw palmetto use 
among 6525 men (22, 24, 28, 34, 36, 51, 54, 56, 58-60); this ranged from 1.9% (60) 
to 24.5% (54).  Eleven studies reported prevalence of selenium use among 7109 men 
(22, 24, 28, 36, 50, 51, 54, 56, 58-60); this ranged from 4.1% (28) to 26.6% (54).  
Eleven studies reported the prevalence of herbal medicine and supplement use among 
5274 men (24, 29, 34-37, 39, 40, 45, 60, 62); this ranged from 1.2% (35) to 21.7% 
(37).  Nine studies reported on use of vitamins among 1734 men (29, 34, 35, 37, 40, 
54, 56, 59, 62); this ranged from 3.6% (62) to 79.3% (54).  These studies reported on 
use of vitamins as an overarching category that was not defined consistently by the 
authors and could include vitamin E and/or multivitamins.  Eight studies reported on 
use of Vitamin E among 3261 men (22, 28, 34, 36, 50, 51, 54, 60); this ranged from 
5.0% (28) to 53.3% (54).   
Factors	related	to	CAM	use	
Visual inspection of scatterplots (not shown) suggested no simple relationship between 
prevalence of CAM use and study-level variables including sample size, study quality, 
geographical location.  Figures 1 and 2 suggest that the prevalence of CAM use might 
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have increased slightly over the past 10 years, although this trend was not statistically 
significant (Pearson’s r (n=39) = 0.25, p=.12).  The evidence concerning individual 
patient-level correlates of CAM use was also limited (see Table 4).  From these studies 
it seems unlikely that CAM use among men with prostate cancer is strongly related to 
marital status or age.  There was more consistent evidence to suggest that CAM use 
might be more likely among men with higher education or higher income, although 
again a number of studies fail to find significant associations.  Similarly, there was 
some evidence that men with more severe or advanced cancer, assessed both at 
diagnosis and subsequently, might be more likely to use CAM.  There was no clear 
relationship between overall study quality as assessed by the QAT and whether or not 
significant relationships were reported between CAM use and patient-level factors. 
Common	reasons	for	CAM	use	
Nine studies (22, 29, 34, 35, 37, 53, 57-59) reported on men’s reasons for CAM use 
(Table 5).  A variety of reasons were either specifically asked about by investigators or 
offered by participants. Commonly reported reasons concerned physical health status 
(e.g. to treat cancer or side-effects) and psychological wellbeing (e.g. to gain a sense 
of control or hope).  Less commonly endorsed reasons related to the respondent’s 
social networks (e.g. recommendations from friends or health care staff). 
Discussion 
The primary studies that we have located and reviewed do not allow us to offer any 
definitive statements concerning the prevalence of CAM use among men with prostate 
cancer.  Indeed, the prevalence of CAM use reported by individual studies ranged from 
8% to 90%, and the high degree of heterogeneity in this literature precluded any formal 
meta-analysis.  Previous reviews of the wider literature on CAM use across multiple 
cancer diagnoses have also found considerable variation across studies (17, 18).  The 
variation in prevalence rates may be a consequence of the varied definitions of CAM 
use utilised in the original studies.  For example, in our primary studies the reported 
time period over which CAM use is assessed ranged from ‘current’ CAM use 
(presumably more akin to incidence than prevalence) through CAM use since diagnosis 
(a varied time for different participants)/ over the past 4 weeks -12 months, to any 
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CAM use ever.  If we focus exclusively on the use of CAM as part of cancer care, then 
the prevalence of CAM use ranged from 8% to 50%.  It is likely that men with prostate 
cancer not only use CAM for cancer care but also for other reasons (e.g. general health, 
other conditions), and many of the studies included in this review did not clearly 
distinguish these two different types of CAM use.  Lack of specificity regarding CAM 
use for cancer care was also encountered in our analysis of the prevalence of use of 
specific CAM modalities.  The five CAM modalities examined most often in the original 
studies were saw palmetto, selenium, herbal medicine/supplements in general, 
vitamins, and vitamin E.  It would seem that vitamins in general and vitamin E in 
particular are used more frequently than saw palmetto, selenium, or herbal 
medicine/supplements in general.  Perhaps vitamin E is more widely available or 
cheaper than saw palmetto or selenium (income does appear to be associated with 
CAM use in this population), or perhaps the negative publicity surrounding PC-SPES 
has encouraged men to use vitamins instead of less well-known supplements.  Some 
supplements have been investigated for prostate cancer prevention (15, 65, 66), but 
clinical studies on their therapeutic use in prostate cancer are rare (67).  It will be 
interesting to see whether supplement use declines in this population, or if new 
supplements are sought out, as a result of major trials, such as SELECT (15).  At 
present, further research on the efficacy and safety of such approaches seems 
warranted given that patients are initiating and/or continuing to use supplements after 
cancer diagnosis and possibly alongside conventional treatments.  Indeed, some of 
these CAMs have the potential to interact with conventional medical treatments in both 
beneficial and detrimental ways (68); consequently oncologists need to encourage 
open dialogue about these interventions to understand whether and what kinds of 
CAM their individual patients are using. 
We examined possible reasons for and correlates of CAM use by exploring 
men’s reasons for CAM use as reported across studies, by assessing the consistency of 
evidence concerning clinical and demographic correlates of CAM use, and by exploring 
possible study-level correlates of CAM use.   We were unable to determine with any 
specificity the most common reasons for CAM use across studies, or to examine how 
men’s reasons for using CAM may differ over time and place.  The use of standardised 
measures would make this possible in future.  Only 9 out of the 42 studies reviewed 
reported men’s reasons for using CAM; commonly reported reasons included wanting 
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to improve or maintain physical health (related to prostate cancer and/or its 
conventional treatment) and psychological wellbeing and outlook.  The variety in 
prevalence rates reported across our studies may be, at least in part, due to differences 
in participants’ perceived un-met needs concerning their health and wellbeing.  It may 
also be partly due to differences in the demographic or clinical characteristics across 
participants in the different studies: there was some evidence that men with higher 
educational achievements or higher incomes are more likely to use CAM, and that men 
with more severe or advanced cancer are more likely to use CAM.  CAM use in the 
general population is also associated with higher education, but is less commonly 
associated with income and the evidence concerning clinical characteristics is mixed 
(69).  We found a weak trend for CAM use to have increased over the past 10 years; 
there was no clear pattern across other study-level factors (quality, location). 
Overall, the quality of the studies was reasonable, and was on average higher 
than the quality of studies in our recent review of CAM use in paediatric cancer 
(median QAT score 66% versus 50% (19)).  We identified common limitations that can 
be overcome in future studies by, firstly, asking participants to report their current 
CAM use that is associated with their cancer care (or by limiting recall periods to less 
than 12 months); secondly, using pilot-tested, validated, and standardised 
questionnaires or interview protocols to measure CAM use (e.g. (70, 71)); and thirdly, 
collecting data from large, representative samples of men with prostate cancer 
identified from population-based registers or, at least, multiple treatment centres. 
The conclusions that can be drawn from this review are limited, primary because 
of the heterogeneity and quality of the original studies but also by our review 
procedures.  While we searched six electronic databases using pre-defined search 
terms, it is possible that we may have missed relevant publications from other sources 
in particular if published in languages other than English. Similarly, studies from the 
USA in particular and the wider English-speaking world dominated our review, and so 
our conclusions should not be generalised beyond these settings.  We considered 
subgroup and sensitivity analyses to explore the heterogeneity of included data. 
However, we did not find convincing criteria for homogeneous subsets of studies 
suitable for pooled analyses such as meta-analysis.  
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Published surveys on the prevalence of CAM use in men with prostate cancer are 
generally of reasonable quality but future studies should use standardised data 
collection tools to decrease methodological heterogeneity and facilitate data pooling in 
future reviews.  Men with prostate cancer do commonly use CAM as part of their cancer 
care, but the prevalence of use varies substantially across studies from 8% to 50%.  
This variation is still greater when taking into account studies that do not focus 
exclusively on CAM use for cancer care.  Oncologists, CAM practitioners, and their 
patients should work towards facilitating open communication about using CAM 
contemporaneously with conventional prostate cancer care.   
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Table 1. 
Summary of Quality Assessment Tool Scores and Reliability 
 
Quality Assessment Tool Item Cohen’s 
Kappa 
Points 
awarded 
(a) 
Frequency 
of studies  
References 
Study Methods:      
Recall bias  .758**    
   Low risk  
   (prospective data collection or current use)  
2  7 (17%) (24, 36, 44, 56, 58, 59, 61) 
   Some risk  
   (retrospective data collection within past 12 months) 
1 16 (38%) (23, 27, 28, 31, 32, 34, 35, 38, 
40-42, 45, 48, 49, 51, 54) 
Piloted questionnaire (or equivalent) .761** 1 20 (48%) (22, 24, 27, 29, 31, 42, 43, 45, 46, 
51-55, 57, 59-63) 
Describe efforts to address potential sources of bias .619** 1 21 (50%) (22, 24, 27, 29-33, 37-39, 42, 43, 
45, 48, 51, 52, 55, 59-61) 
Adjust for potential confounders in statistical analysis 
(b) 
.847*** 1 27 (68%)  (22-24, 27, 28, 30-33, 38-43, 45, 
46, 48, 49, 52, 54-59, 61) 
Sampling:     
Response rate reported (c) .858*** 1 32 (78%)  (22, 23, 25-33, 35, 37, 39, 41-43, 
45, 48, 49, 51-56, 58-63) 
Representative sampling strategy .478* 1 18 (43%) (22-24, 27, 29, 30, 32, 38, 39, 
41-43, 49, 50, 52, 53, 58, 61) 
Reporting of participants’ characteristics: 
Time since diagnosis .905*** 0.5 23 (55%) (22, 24, 27, 29-33, 35, 39, 41, 42, 
45, 47-50, 53, 54, 56, 59, 60, 63) 
Stage of cancer .854*** 0.5 26 (62%) (22-24, 27, 28, 30, 31, 33, 34, 36, 
40, 42, 43, 45, 48-51, 53, 55, 58-
63) 
Indicator of socio-economic status  
(e.g. income, education) 
.869*** 0.5 32 (76%) (22, 24-30, 32, 33, 35, 37, 39, 41, 
42, 45, 46, 48, 49, 51-63) 
Age .844*** 0.5 39 (93%) (22, 23, 25-43, 45-56, 58-63) 
Ethnicity .901*** 0.5 26 (62%) (22, 24, 26, 28-30, 32, 33, 35, 36, 
39, 41-46, 48, 49, 51, 52, 54, 57, 
59-61) 
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CAM Use     
CAM clearly defined to participants .779** 2 34 (81%) (22-24, 28, 30-32, 34-47, 49-53, 
55, 57-63) 
Assessed CAM use for cancer care or since cancer 
diagnosis 
.674** 2 26 (62%) (22, 24, 27-32, 34, 35, 39, 40, 
42-45, 48, 51, 53-60) 
Definition of CAM reported in paper .837*** 1 30 (71%) (22, 23, 25, 28-30, 33, 35-37, 40, 
42, 44-50, 52, 53, 55-63) 
Use of CAM modalities assessed 1.00*** 1 42 (100%) (22-63) 
* Moderate agreement (0.41-0.60).  ** Substantial agreement (0.61-0.80).  *** Almost perfect agreement (0.81-1.00). (21). 
(a) Points were awarded for each item on the quality assessment tool and a total score was then calculated for each study (as a %, 
see text for details).  This enabled the reporting quality of individual studies to be summarised numerically for comparison and 
further analysis.  Individual studies’ total scores are reported in Table 2. 
(b) 2 studies did not examine correlates of CAM use and so were not judged on this criterion 
(c) 1 study could not report a response rate (data were obtained from insurance records) and so was not judged on this criterion. 
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Table 2 
Characteristics of Included Studies 
 
Citation Year Place N CAM 
use 
(%) 
QAT 
score 
(%) 
Respondents’ 
disease 
characteristics  
Operational definition of CAM use 
Studies that focus exclusively on men with prostate cancer
Boon et al 
(22) 
2003 Canada 534 30 87 2-3 years since 
diagnosis; 80% 
diagnosed at 
stage A or B. 
CAM used for cancer care, where CAM is “the broad domain of healing 
resources that encompass all health systems, modalities, and practices 
and their accompanying theories and beliefs, other than those intrinsic 
to the politically dominant health system of a particular society or 
culture in a given historical period.” (p.850) 
Chan et al 
(24) 
2005 USA 2582 33 84 6months – 4 
years post 
diagnosis;  
Current CAM use (assessed at multiple time points), defined through a 
check-list of 52 specific modalities and space for additional modalities 
(named modalities included “19 herbals, 12vitamins, minerals, and 
nutritional supplements, 3 diet-modification items, 5 items on 
meditation, massage and bodywork, acupuncture and acupressure, and 
Asian medicine, 3 homeopathic items, and 7 miscellaneous CAM.” 
(p1224) 
Diefenbach 
et al (28) 
2003 USA 417 19 71 Mean PSA at 
diagnosis = 8.9 
(SD =12.8); 
Mean Gleason 
score at 
diagnosis =  6.3 
(SD=1.0)  
CAM use initiated after cancer diagnosis, where CAM is defined through 
a checklist of  42 therapies based on literature and internet searches 
and which were " grouped into categories suggested by the National 
Institutes of Health Office of Alternative Medicine" (p.167) 
Eng et al 
(29) 
2003 Canada 451 12 
(a) 
65 Mean time since 
diagnosis = 13 
months 
(SD=3.9) 
CAM used for cancer care, where CAM is " an approach to diagnosis, 
treatment, and care that falls outside of conventional therapies widely 
used in North America" (p.212) 
Hall et al 
(34) 
2003 USA 238 37 48 All at clinical 
stage T1c - T3 
CAM used for cancer care in the past month, where CAM is defined for 
participants as vitamins, herbal medicines, dietary therapy, or ‘other 
complementary or alternative forms of healthcare ‘ (p606) 
Jones et al 
(36) 
2002 USA 84 37 48 T1 38%; T2 23%;
T3 13%; T4 0%; 
unknown T 13%; 
M1 11% 
Current CAM use where CAM "included any unproved therapy used by 
patients with cancer for (a) treatment of their cancer or other medical 
diagnosis [our emphasis]; (b) management of symptoms related to 
cancer; (c) management of side effects of a conventional cancer 
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treatment; or (d) prevention of an additional cancer.”  (p 273)
Kao et al 
(37) 
2000 USA 46 37 45 CAM use, where CAM "encompass a wide range of therapies the efficacy 
of which has not been proven, as determined by the National Institute 
of Health Office of Alternative Medicine” (p615) and was defined on the 
patient questionnaire as herbal remedies (e.g. saw palmetto, coenzyme 
Q, garlic), old time remedies (e.g. hot toddies), vitamin therapy (high 
dose vitamins), and special diets (e.g. macrobiotic).    
Lee et al 
(39) 
2002 USA 543 30 71 1-3 years post 
diagnosis 
CAM used for cancer care, where CAM is “macrobiotic diet, megavitamin 
therapy, and other dietary methods (i.e., low-fat or vegetarian diets, 
homeopathy, herbal remedies, and psychologic methods, such as 
meditation or imagery; faith and spiritual healing; and physical 
methods, including massage, relaxation, acupressure, and 
acupuncture)” (72 p.42)  
Lippert et 
al (40) 
1999 USA 190 43 58 T1 40%; T2 46%;
T3 2% 
CAM used for cancer care in the past month, where CAM is “therapies 
that are unproven” (p2643) and a checklist of 18 items (plus ‘other’) is 
given to participants. 
Ponholzer 
et al (50) 
2003 Austria 822 30 42 Mean time since 
diagnosis = 3.9 
years (SD 3.1); 
11.5% 
metastases at 
diagnosis. 
Previous or current CAM use, where CAM is " any kind of supportive 
measures used to complement evidence based treatment"(p604) and 
participants were given a list of CAM therapies. 
Porter et al 
(51) 
2008 USA 177 50 76 Mean pre-
treatment 
Gleason Score = 
6.2 (SD 0.81).  
Mean current 
PSA level 
1.3ng/ml (SD 
2.3) 
Current CAM use for prostate health, assessed with a list of 17 
modalities (“10 biologically based therapies, of which there were 6 
dietary supplements, 1 dietary system and 3 nutritional foods, and 7 
non-biologically based therapies of which there were 5 mind-body 
therapies and 2 spiritually based therapies” (p320) 
Sheriff et al 
(54) 
2005 USA 184 90 58 1 year or less 
post diagnosis 
Any vitamin/supplement use since cancer diagnosis (excluding multi-
vitamins). 
Steginga et 
al (56) 
2004 Australia 111 25
(b) 
61 At baseline, 
mean time since 
diagnosis = 4 
weeks (SD 4.6) 
Current CAM use (at baseline = average 4 weeks post cancer diagnosis), 
where CAM is "Treatments that are used specifically to alter the course 
of the cancer and that are not used as standard medical treatments 
because of their non-medical nature or lack of proven efficacy" (p72) 
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Wilkinson 
et al (58) 
2002 USA 1099 18 81 - Current CAM use, defined as "supportive methods used to complement 
evidence based treatment"  (p2505) with an exclusive focus on 
“nutritional interventions including herbs, vitamins and minerals” 
(p2506) 
Wilkinson 
et al (59) 
2008 UK 294 25 93 At least 5yrs 
post diagnosis 
16%; 4yrs post 
diagnosis 12%; 
3yrs post 
diagnosis 19%; 2 
yrs post 
diagnosis 24%; 
<=1yr post 
diagnosis 25%.  
Currently no 
evidence of 
cancer 45%; 
Currently cancer 
present 32%. 
Current CAM use, assessed through list of 30 modalities and open 
questions, where CAM is "'a broad domain of healing resources that 
encompasses all health systems, modalities, and practices and their 
accompanying theories and beliefs, other than those intrinsic to the 
politically dominant health systems of a particular society or culture in a 
given historical period" (Ernst & White 2000” (p492) 
Wiygul et 
al (60) 
2005 USA 805 73
(c) 
74 Median time 
post diagnosis = 
40 months.  
Loco-regional 
disease 95%, 
Distant disease 
2%. 
Current and ever use of CAM, where the focus is on supplements 
defined as vitamins, minerals, and herbals. 
Yoshimura 
et al (62) 
2003 Japan 138 20 48 T1 53%; T2 12%; 
T3 36% 
Ever used CAM, defined as "therapies the efficacy of which has not been 
proven" (p26) and assessed with a 17 item checklist (plus ‘other’). 
  
Studies in which men with prostate cancer are a sub-sample of a larger sample including other cancer diagnoses 
Bruns et al 
(23) 
2006 Germany 81 47 58 - CAM use within the past 4 weeks, where CAM is "diverse medical and 
health care systems, practices, and products that are presently not 
considered to be part of conventional medicine, as practiced by holders 
of M.D. (medical doctor) degrees and by their allied health 
professionals" (p318) and assessed by a list of 10 modalities (special 
diets, psychotherapy, movement and physical therapy, mind/body 
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therapies, spiritual practices, nutrition co-factors and supplements, 
traditional Chinese medicine, immuno-augmentative treatment, other 
approaches, other unconventional approaches).   
Cheung et 
al (25) 
2004 Hong 
Kong 
18 28 26 2 – 24 months 
since 
completing 
radiation 
therapy 
CAM use, where CAM is "used as an adjunct to mainstream cancer 
medicine for symptom management and to enhance cancer medicine 
for symptom management and to enhance quality of life. Ernst and 
Cassileth gave a more detailed definition: "diagnosis, treatment and/or 
prevention which complements mainstream medicine by contributing to 
a common whole, by satisfying a demand not met by orthodox methods 
or by diversifying the conceptual framework of medicine"." (p7)  
Chrystal et 
al (26) 
2003 New 
Zealand 
18 50 23 - CAM use where CAM is not clearly defined in the paper.
Corner et 
al (27) 
2009 England 42 14 71 6months or less 
post diagnosis 
CAM used since cancer diagnosis, where CAM is defined on the basis of 
“both the House of Lords Science and Technology Select Committee 
(2000) definition of CAM and Thomas et al.’s (2001) questionnaire-
based survey.”  (p.272) 
Gansler et 
al (30) 
2008 USA 814 (d) 81 10-24 months 
post diagnosis 
CAM used for cancer care, where CAM is "the broad range of 
scientifically unproven treatments and practices that are not presently 
considered part of conventional medicine" (p1048) and CAM use is 
assessed with a 19-item checklist. 
Girgis et al 
(31) 
2005 Australia 64 13 74 At least 3 
months post 
diagnosis 
CAM used for cancer care or related symptoms over the past 6 months, 
where CAM is not clearly defined/operationalised in the paper.   
Goldstein 
et al (32) 
2008 USA 241 (e) 77 - CAM use in general and for cancer care, where CAM is defined through 
a list of 11 CAM providers, special diets, 32 dietary supplements, self-
directed prayer, support groups, 8 unconventional cancer therapies(e.g. 
chelation). 
Gotay (33) 1999 USA 99 28 48 4-6 months 
post diagnosis 
CAM use, where CAM " is a broad domain of healing resources that 
encompasses all health systems, modalities, and practices and their 
accompanying theories and beliefs…CAM includes all such practices 
and ideas self-defined by their users as preventing or treating illness or 
promoting health and well-being." (p49) 
Hann et al 
(35) 
2005 USA 82 (f) 65 1-12 months 
post diagnosis 
(Mean = 5 
months) 
Current CAM use, where CAM was defined following "the American 
Cancer Society as 'those [methods] that patients use along with 
conventional medicine'." (p284) and assessed with a 44-item checklist.   
Lafferty et 
al (38) 
2004 USA 782 12 52 - CAM use during year 2000, where CAM use is a visit to one of four 
types of practitioner:  Chiropractor, Naturopath, Acupuncturist, 
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Massage Practitioner
Mao et al 
(41) 
2007 USA 195 26 58 - CAM use over the past 12 months, where CAM is 27 named therapies 
(10 provider-based and 17 not necessarily provider-based). 
Mao et al 
(42) 
2008 USA 93 44 94 3.5-4 years post 
diagnosis 
CAM use for cancer care in the past year, where CAM "represents a 
group of health practices that are not routinely taught in medical 
schools or provided in hospitals"(p117) and is assessed through 
questions about 11 specific CAM modalities. 
Maskarinec 
et al (43) 
2000 USA 242 19 74 Diagnosis of 
invasive cancer 
during 1996 
CAM use since diagnosis where CAM is defined for participants with a 
list of 21 therapies (plus ‘other alternative therapy’).   
Metz et al 
(44) 
2001 USA 51 37 55 - Current CAM use, where CAM is "any unproven therapy utilized by a 
cancer patient for treatment of their cancer or other medical diagnosis, 
management of symptoms related to cancer, management of side 
effects of a conventional cancer treatment, or prevention of an 
additional cancer" and specific questions to participants name vitamins, 
herbal supplements, guided imagery, biofeedback, meditation, shark 
cartilage or “any other natural supplement” (p150). 
Miller et al 
(45) 
2009 USA 115 77 87 4-8 years post 
diagnosis (Mean 
= 6 years) 
Use of one (or more) dietary supplements at least once a week for the 
past month, where dietary supplements " include products containing 
vitamins and minerals as well as herbs or other botanicals, amino acids, 
glandular extracts or other non-nutrient ingredients" (p61) and are 
measured with a 34-item checklist and open-ended questions. 
Molassiotis 
et al (46) 
2005 Europe 30 30 48 - CAM use, where CAM is " 'any diagnosis, treatment or prevention that 
complements mainstream medicine by contributing to a common 
whole, by satisfying a demand not met by orthodoxy or by diversifying 
the conceptual framework of medicine'"(p1 of 9) and is assessed with a 
checklist of 26 therapies (plus ‘other’).   
Newsom-
Davis et al 
(47) 
2009 UK 33 24 32 Included newly 
diagnosed and 
long-term 
follow-up 
patients 
CAM use, where CAM is "any medicine, vitamin supplement or food 
supplement not prescribed by an allopathic doctor" (p312). 
Paltiel et al 
(48) 
2001 Israel 38 37 
(g) 
68 At least 2 
months post 
diagnosis 
CAM use since cancer diagnosis, where CAM is "any therapy not 
included in the orthodox biomedical framework of care for patients with 
cancer (including homeopathy, special diets such as macrobiotic or 
homeopathic diet, fasting, therapeutic enemas, megavitamins, 
metabolic therapy, naturopathy, reflexology, massage, acupuncture, 
26 
 
and healing" (p 2440)
Patterson 
et al (49) 
2002 USA 114 59 68 24 months or 
less since 
diagnosis 
CAM use over the past 12 months, where CAM is "health care and 
medical practices not currently an integral part of conventional 
medicine" (p478) and participants were specifically asked about 
alternative providers (acupuncturists, naturopaths, spiritual advisors), 
mental or other therapies (e.g. biofeedback, hypnotism, guided 
imagery), and vitamin mineral herbal or other supplements.   
Ross et al 
(52) 
2008 USA 350 62 68 - Use of prayer for own health, ever.  
Salmenpera 
(53) 
2002 Finland 190 27 71 52% more than 2 
years post 
diagnosis.  16% 
had metastases 
at time of study. 
CAM use since cancer diagnosis, where CAM is "treatments whose 
effectiveness has not been scientifically established and are therefore 
not covered by legislation governing official medicine" (p44) 
Sollner et 
al (55) 
2000 Austria 12 8 74 - CAM use ever, assessed by a list of 16 therapies and defined as: 
"alternative therapies are treatments that are used specifically to 
influence the course of cancer and that are not used as standard 
medical treatments because of their nonmedical character or the lack of 
proven efficacy; complementary therapies are treatments aimed at 
symptom control or enhancing the quality of patients lives" (p.874) 
Vapiwala et 
al (57) 
2006 USA 77 39 58 - CAM use since cancer diagnosis, where CAM forms listed for 
participants were: “herbal supplements, soy or other phytoestrogen-
containing products, omega-3 fatty acid supplements, medicinal skin 
balms and salves, acupuncture, massage therapy and guided imagery” 
(p468).   
Wyatt et al 
(61) 
1999 USA 206 32 84 - Current use of CAM assessed with a checklist of 17 items where CAM is 
defined as:  " ‘ a broad domain of healing resources that encompasses 
all health systems, modalities, practices and their accompanying 
theories and beliefs, other than those intrinsic to the politically 
dominant health system of a particular society or culture in a given 
historical period’" and "therapies used along with conventional medicine 
that are non-invasive, pleasant, stress-reducing, and can be used in 
states of sickness or health"" (p136) 
Yoshimura 
et al (63) 
2005 Japan 171 47 52 1 year post 
diagnosis 
Ever used CAM, defined as "the set of treatments whose efficacy has not 
been proven by the National Institutes of Health Office of Alternative 
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Medicine" (p685) and assessed with an 18 item checklist.
a. This figure is prevalence of CAM use specifically for cancer.  The paper also reports prevalence of CAM use in general (= 39%) 
b. This figure is prevalence of CAM use at baseline.  The paper also reports prevalence of CAM use 12 months post-baseline (14%) 
and 2 months post-baseline (16%), where baseline is, on average, 4 weeks post-diagnosis.  
c. Overall prevalence of CAM use in relation to cancer is not reported (although use of specific modalities in relation to cancer 
care is reported). 
d. Overall prevalence of CAM use is not reported for prostate cancer only (paper reports a breakdown into NCCAM categories, 
which are not mutually exclusive). 
e. Overall prevalence of CAM use is not reported for prostate cancer only (paper reports a breakdown into three non-mutually 
exclusive categories – use of CAM provider, use of dietary/nutritional supplement/use of other CAM therapy, some of which are 
further separated into use to treat cancer or prevent cancer recurrence). 
f. Overall prevalence of CAM use is not reported for prostate cancer only (paper reports a breakdown into specific individual CAM 
modalities which are not mutually exclusive). 
g. This figure is prevalence of CAM use since diagnosis.  The paper also reports prevalence of CAM use in the past 3 months 
(2.6%). 
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Table 3.  Percentage of participants using different types of conventional treatments for prostate cancer 
 
Study Radical 
prostatectomy/ 
‘surgery’ 
Hormone 
therapy 
(External beam) 
radiation therapy
Brachy-
therapy 
Watchful 
waiting/ 
surveillance 
Combined and other treatments  
Boon (22) 37 (RP) 35 35 7 10 1 (Other) 
Bruns (23) - - - - - 100 (unspecified radiation therapy)- 
Cheung (25) - - - - - 100 (unspecified radiation therapy)- 
Diefenbach (28) 15 (S) - 54 25 5 - 
Eng (29) 29 (a) (RP) 16 42 (a) 8 10 3 (Orchiectomy) 
2 (not started treatment) 
1 (declined conventional treatment) 
Hall (34) 44 (RP) - - 22 - 34 (brachytherapy & external beam 
radiation) 
Hann (35) 42 (S) 27 - - - 46 (unspecified radiation therapy) 
4 (Chemotherapy) 
1 (Bone marrow transplant) 
1 (Immuno-therapy) 
Kao (37) - - - - - 100 (unspecified radiation therapy) 
Lippert (40) 21 (RP) - - 48 - 31 (brachytherapy & external beam 
radiation) 
Ponholzer (50) 54 (RP) 23 12 - - 7 (radiotherapy & endocrine therapy) 
4 (unspecified) 
Sheriff (54) 57 (RP) - - - - 32 (unspecified) 
10 (no conventional treatment) 
Steginga (56) 56 (RP) - - - 26 18 (unspecified radiation therapy) 
Wilkinson (58) 45 (RP) 12 12 3 13 1 (cryotherapy) 
4 (prostatectomy & hormonal 
therapy) 
4 (prostatectomy & external beam 
radiation) 
Wilkinson (59) 39 (S) 38 40 9 6 - 
Wiygul (60) 76 (S) - 6 (a) - - 18 (unspecified) 
Yoshimura (62) 68 (RP) - 32 (a) - - - 
Note: Categories not always mutually exclusive.  
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(a) with or without hormone therapy 
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Table 4 
Summary of Evidence of Patient-Level Correlates of CAM Use 
Demographic 
or Clinical 
Factor  
Number of studies 
testing association 
with CAM use 
Number (and %) of studies finding significant 
association with increased CAM use 
Number (and %) of studies finding no 
significant association 
Younger age 14  2 studies (14%) (22, 59) 
 All score >50% on QAT 
12 studies (86%) (28, 29, 35-37, 39, 40, 50, 
56, 58, 60, 62) 
 8 score >50% on QAT 
Marital Status 8  0 (0%) 8 studies (100%) (22, 24, 28, 29, 35, 39, 58, 
59) 
 All score >50% on QAT 
Higher (i.e. 
more) 
education 
13  7 studies (54%) (24, 28, 35, 37, 39, 58, 60) 
 6 score >50% on QAT 
6 studies (46%) (22, 29, 54, 56, 59, 62) 
 4 score >50% on QAT 
Higher income 7  3 studies (43%) (24, 37, 58) 
 2 score >50% on QAT 
4 studies (57%) (22, 39, 59, 62) 
 3 score >50% on QAT 
Increased 
cancer severity 
or stage at 
diagnosis 
8  4 studies (50%) (22, 24, 40, 62) 
 3 score >50% on QAT 
4 studies (50%) (28, 36, 50, 59) 
 2 score >50% on QAT 
Worse current 
cancer status 
6  3 studies (50%) (22, 53, 58) 
 All score >50% on QAT 
3 studies (50%) (50, 59, 60) 
 2 score >50% on QAT 
Ethnicity 7  2 studies (29%) report white men more likely to use 
CAM than non-white men (36, 60)  
 1 scores >50% on QAT 
1 study (14%) reports ethnic minority men more 
likely to use CAM than white men (28)  
 Scores >50% on QAT 
4 studies (57%) (24, 35, 54, 59) 
 3 score >50% on QAT 
Conventional 
treatment 
7  3 studies (43%) find CAM use varies with 
conventional treatment (conventional treatments 
differ across individual studies) (50, 58, 59) 
 2 score >50% on QAT 
4 studies (57%) (40, 54, 60, 62) 
 2 score >50% on QAT 
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Table 5. 
Summary of Reasons for CAM use 
 
Extent of Endorsement by Participants Reasons for CAM use 
  
Very common(by >50% of respondents 
in any one study) 
To cure cancer, to prevent recurrence or 
spread of cancer, to increase life 
expectancy, to improve quality of life, to 
relieve symptoms in general, to have 
more control over recovery, to give 
hope, to play a more active role in 
recovery, to boost immune system, to 
help manage stress, to manage or treat 
side-effects of conventional treatment. 
  
Common (by 25-50% of respondents in 
any one study) 
To ‘feel better’, to improve general 
overall health, to slow disease 
progression, to have a greater sense of 
control over cancer, for psychological 
support, because it is completely safe. 
  
Less common (by <25% of respondents 
in any one study) 
Because of medical or scientific 
information, because friends had good 
experiences of CAM, wanted to 
experiment, recommended by health 
care professional, because of current 
poor health status, disappointed by or 
not satisfied with conventional 
treatment, healthcare staff disinterested, 
because it is giving good results, to 
manage specific cancer symptoms (e.g. 
pain, fatigue), to experience a more 
holistic approach, to have a more 
involved relationship with a practitioner, 
felt pressured by family or friends 
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Figure Legends 
 
Figure 1.  Prevalence of CAM use in prostate cancer. 
Figure 2.  Prevalence of use of specific CAM modalities in prostate cancer. 
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